Dulaglutide: evidence, FDA status and research

It is a weekly shot that lowers blood sugar in type 2 diabetes. Large trials also showed fewer heart attacks and strokes, and it causes only small weight loss.

Sold for

Dulaglutide is talked about as a once-weekly GLP-1 injection that lowers blood sugar, protects the heart and helps with weight.

Studies say

Large randomized trials support the diabetes and cardiovascular indications, which earns an A for those uses; weight loss is a side effect of a few kilograms, not a tested indication.

Why grade A. The glucose-lowering use is supported by the AWARD program of randomized trials, of which AWARD-5 (n=1,098, 52 weeks against sitagliptin) is cited here, and the cardiovascular claim by REWIND, a placebo-controlled trial of 9,901 patients followed for a median of 5.4 years. Weight loss with dulaglutide is modest and it has no obesity indication, so that off-label use would grade lower. ¹²³

FDA. Approved. Dulaglutide is sold as Trulicity (Eli Lilly), approved by the FDA in 2014 as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes in adults and, since 2022, in children aged 10 and older, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes who have cardiovascular disease or multiple risk factors. It is not approved for weight loss. ¹

Written from 4 cited sources. Fact-checked 2026-10-27: 20 claims checked, 3 corrected. Last refreshed 2026-10-27. Not physician reviewed.

What this means for you

What people take it for: Controlling blood sugar in type 2 diabetes
Can a US doctor prescribe it?: Yes, FDA approved for type 2 diabetes and lowering heart risk in people with diabetes.
Properly tested in people?: Yes, in large controlled trials. One trial followed 9,901 people for about 5 years.

Evidence checklist

Randomised controlled trial AWARD trials; REWIND placebo-controlledyes
Human study over 100 people REWIND, 9,901 patientsyes
More than one research group Several trials; approved indicationsyes
Clinical outcomes, not surrogate markers REWIND: major cardiovascular eventsyes
Human safety data beyond case reports Large trials; boxed thyroid warningyes

Drawn from the cited studies below. A dash means the sources give no information.

What it is

Dulaglutide is a long-acting GLP-1 receptor agonist. It joins two modified copies of the gut hormone GLP-1 to a piece of a human antibody (an IgG4 Fc region). This makes the molecule too big for the kidney to clear quickly. It also shields the molecule from DPP-4, the enzyme that destroys natural GLP-1 within minutes. So the drug stays active for a week after one injection under the skin. ¹

Trulicity was approved in September 2014. It became one of the most prescribed diabetes injectables. Then semaglutide and tirzepatide overtook it. It comes in a pen that you use once. ¹

How it works

The gut releases GLP-1 after eating. Dulaglutide activates its receptor on pancreatic beta cells. This raises insulin release, but only when glucose is high. It also suppresses glucagon, the hormone that tells the liver to make sugar. It slows stomach emptying and acts on appetite centers in the brain. That is why GLP-1 drugs reduce food intake. The insulin effect depends on glucose. So dulaglutide alone rarely causes hypoglycemia. ¹

What human research shows

AWARD-5 randomized 1,098 adults with type 2 diabetes that metformin did not control well. They got dulaglutide at two doses, sitagliptin or placebo. At 52 weeks both dulaglutide doses lowered HbA1c more than sitagliptin. HbA1c is the three-month average blood sugar marker. The drops were 0.9 to 1.1 percentage points versus 0.4 for sitagliptin. Dulaglutide also cut body weight more (about 2.6 to 3.0 kg against 1.5 kg). Nausea affected 17% of patients at the higher trial dose, compared with 5% on sitagliptin. ²

REWIND enrolled 9,901 adults with type 2 diabetes. Only 31.5% had established cardiovascular disease. Researchers followed them for a median of 5.4 years. The combined measure was cardiovascular death, non-fatal heart attack or non-fatal stroke. It occurred in 12.0% of dulaglutide patients and 13.4% of placebo patients (hazard ratio 0.88, a 12% lower relative risk). Fewer strokes drove most of the result. Dulaglutide was the first GLP-1 drug to show heart benefit in a group that was mostly preventing a first event. ³

DIADEMA was an open-label randomized trial at one centre in Cairo. It assigned 80 teenagers to weekly dulaglutide or basal-bolus insulin for 24 weeks. Their diabetes came from iron overload in transfusion-dependent thalassaemia. Dulaglutide lowered glucose swings, the main outcome. It also lowered HbA1c and serum ferritin. Swings rose in the insulin group. Nobody had a serious adverse event. This was one centre and a rare form of diabetes, outside the approved use. So it is a hint for more study. It is not a reason to change the label. ⁴

Study	Model	Finding
AWARD-5	Humans, n=1,098, randomized double-blind, 52 weeks vs sitagliptin	Dulaglutide lowered HbA1c more than sitagliptin at both doses, with more nausea. ²
REWIND	Humans, n=9,901, randomized placebo-controlled, median 5.4 years	Major cardiovascular events fell by 12% relative to placebo, mainly through fewer strokes. ³
Trulicity prescribing information 2026	FDA label	Approved for glycemic control in type 2 diabetes from age 10 and for cardiovascular risk reduction in adults; boxed warning for thyroid C-cell tumors. ¹
DIADEMA (Adly 2026)	Humans, n=80 adolescents with thalassaemia-induced diabetes, randomized open-label vs insulin, 24 weeks	Lower glucose variability, HbA1c and ferritin than with insulin; no serious adverse events. ⁴

Safety

Gut effects dominate. They include nausea, diarrhea, vomiting and belly pain, and they are worst in the first weeks. The label has a boxed warning about thyroid C-cell tumors seen in rodents. People with a personal or family history of medullary thyroid carcinoma or MEN 2 must not take it. Other warnings cover pancreatitis, gallbladder disease, acute kidney injury from dehydration and diabetic retinopathy complications. Hypoglycemia is also a risk when it is combined with insulin or sulfonylureas. ¹

In REWIND, serious adverse events were no more frequent on dulaglutide than on placebo over five years. This is the longest controlled safety follow-up for the drug. ³

Questions for your clinician

How much weight loss is realistic, given it has no obesity indication?
Do I have any risk factors that rule this drug out?
How does it compare with other GLP-1 drugs for my heart risk?

Questions people ask

Is dulaglutide FDA-approved?

Yes. Trulicity has been approved since 2014 for type 2 diabetes. Since 2020 it is also approved to reduce major cardiovascular events in adults with type 2 diabetes. The use in children from age 10 was added in 2022. ¹

Is dulaglutide approved for weight loss?

No. Trial participants lost a few kilograms on average. But dulaglutide has no obesity approval. No large trial has tested it in people without diabetes. Semaglutide, liraglutide and tirzepatide have their own obesity approvals. Dulaglutide does not. ¹²

How does dulaglutide compare with semaglutide?

Both are weekly GLP-1 drugs for type 2 diabetes, and both help the heart. Head-to-head blood sugar data (not cited here) favor semaglutide for HbA1c and weight. Dulaglutide's heart trial stood out. Most of its participants were trying to prevent a first event. ³

What are the main risks?

Nausea and other gut effects are common. The serious warnings are pancreatitis, gallbladder disease, kidney injury from dehydration and worse diabetic retinopathy. The boxed warning comes from a thyroid tumor signal in rodents. ¹

Citations

FDA 2026: Trulicity (dulaglutide) prescribing information accessdata.fda.gov
Nauck 2014, Diabetes Care: dulaglutide versus sitagliptin after 52 weeks (AWARD-5) doi.org
Gerstein 2019, Lancet: dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND) doi.org
Adly 2026, Diabetologia: dulaglutide versus insulin in adolescents with thalassaemia-induced diabetes (DIADEMA) pubmed.ncbi.nlm.nih.gov

Updates

2026-10-27 added DIADEMA RCT, dulaglutide vs insulin in 80 adolescents with thalassaemia-induced diabetes (PMID 42618811) to human findings and key studies.